Study Finds Limited Impact Of New FDA Rule On 30-Month Stays In Drug Patent Challenges
Last year's decision by the U.S. Food and Drug Administration to limit 30-month stays in pharmaceutical patent challenges isn't likely to ease the pathway to the market for generic makers, according...To view the full article, register now.
Already a subscriber? Click here to view full article